CNBC Television
@CNBCtelevision·3.4M subscribers·157.5K videos
GW Pharma CEO: Europe Epidyolex Launch | Mad Money | CNBC
Posted
September 27, 2019
Views
799
Likes
3
Comments
1
Engagement
September 27, 2019
799
3
1
0.50%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Episode Timeline
Every episode in order around the one you’re watching — click any card and the page flips straight to it.
7:03Now PlayingThe European Union has approved GW Pharma’s CBD-based drug Epidyolex to treat seizures related to epilepsy. CEO Justin Gover explains its prospects to Jim Cramer and what it means for drug research.
» Subscribe to CNBC
» Watch more Mad Money here
» Read more about GW Pharma
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Get More Mad Money!
Read the latest news
Watch full episodes
Follow Mad Money on Twitter
Like Mad Money on Facebook
Follow Cramer on Twitter
Connect with CNBC News Online!
Visit CNBC.com
Find CNBC News on Facebook
Follow CNBC News on Twitter
Follow CNBC News on Google+
Follow CNBC News on Instagram
GW Pharma CEO: Europe Epidyolex Launch | Mad Money | CNBC
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
